A Multicenter, Single-arm Study of the Efficacy and Safety of Selinexor Combined With Venetoclax as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia/Myelodysplastic Syndrome
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs Selinexor (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 15 Jan 2025 New trial record